Journal
CARDIOVASCULAR RESEARCH
Volume 114, Issue 1, Pages 12-18Publisher
OXFORD UNIV PRESS
DOI: 10.1093/cvr/cvx149
Keywords
Empagliflozin; EMPA-REG OUTCOME; Diabetes; Heart failure; Sodium; Mitochondria
Categories
Funding
- Deutsche Forschungsgemeinschaft (DFG) [SFB 894, Ma 2528/7-1]
- Corona Stiftung
Ask authors/readers for more resources
The effects of intense glycaemic control on macrovascular complications in patients with type 2 diabetes are incompletely resolved, and many glucose-lowering medications negatively affect cardiovascular outcomes. Recently, the EMPA-REG OUTCOME trial revealed that empagliflozin, an inhibitor of the sodium-glucose cotransporter 2 (SGLT2), substantially reduced the risk of hospitalization for heart failure, death from cardiovascular causes, and all-cause mortality in patients with type 2 diabetes mellitus at high cardiovascular risk. Although several mechanisms may explain this benefit, plasma volume contraction and a metabolic switch favouring cardiac ketone bodies oxidation have recently been proposed as the major drivers. Recent experimental work has prompted a novel and intriguing hypothesis, according to which empagliflozin may reduce intracellular sodium (Nathorn) load observed in failing cardiac myocytes by inhibiting the sarcolemmal Nathorn/Hthorn exchanger. Since elevated intracellular Nathorn hampers mitochondrial Ca2+ thorn handling and thereby, deteriorates energy supply and demand matching and the mitochondrial antioxidative defence systems, empagliflozin may positively affect cardiac function by restoring mitochondrial function, and redox state in the failing heart. Here, we review the current evidence for such a third mechanistic hypothesis, which may foster heart failure and diabetes research into a new direction which harbours several potential targets for therapeutic intervention.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available